TY - JOUR
T1 - Investigating interferences of a whole-blood point-of-care creatinine analyzer
T2 - Comparison to plasma enzymatic and definitive creatinine methods in an acute-care setting
AU - Straseski, Joely A.
AU - Lyon, Martha E.
AU - Clarke, William
AU - DuBois, Jeffrey A.
AU - Phelan, Lois A.
AU - Lyon, Andrew W.
PY - 2011/11
Y1 - 2011/11
N2 - BACKGROUND: Although measurement of whole-blood creatinine at the point of care offers rapid assessment of renal function, agreement of point-of-care (POC) results with central laboratory methods continues to be a concern. We assessed the influence of several potential interferents on POC whole-blood creatinine measurements. METHODS: We compared POC creatinine (Nova Stat- Sensor) measurements with plasma enzymatic (Roche Modular) and isotope dilution mass spectrometry (IDMS) assays in 119 hospital inpatients. We assessed assay interference by hematocrit, pH, pO 2, total and direct bilirubin, creatine, prescribed drugs, diagnosis, red blood cell water fraction, and plasma water fraction. RESULTS: CVs for POC creatinine were 1.5- to 6-fold greater than those for plasma methods, in part due to meter-to-meter variation. Regression comparison of POC creatinine to IDMS results gave a standard error (S y|x) of 0.61 mg/dL (54 μmol/L), whereas regression of plasma enzymatic creatinine to IDMS was S y|x 0.16 mg/dL (14 mol/L). By univariate analysis, bilirubin, creatine, drugs, pO 2, pH, plasma water fraction, and hematocrit were not found to contribute to method differences. However, multivariate analysis revealed that IDMS creatinine, red blood cell and plasma water fractions, and hematocrit explained 91.8% of variance in POC creatinine results. CONCLUSIONS: These data suggest that whole-blood POC creatinine measurements should be used with caution. Negative interferences observed with these measurements could erroneously suggest adequate renal function near the decision threshold, particularly if estimated glomerular filtration rate is determined. Disparity between whole-blood and plasma matrices partially explains the discordance between whole-blood and plasma creatinine methods.
AB - BACKGROUND: Although measurement of whole-blood creatinine at the point of care offers rapid assessment of renal function, agreement of point-of-care (POC) results with central laboratory methods continues to be a concern. We assessed the influence of several potential interferents on POC whole-blood creatinine measurements. METHODS: We compared POC creatinine (Nova Stat- Sensor) measurements with plasma enzymatic (Roche Modular) and isotope dilution mass spectrometry (IDMS) assays in 119 hospital inpatients. We assessed assay interference by hematocrit, pH, pO 2, total and direct bilirubin, creatine, prescribed drugs, diagnosis, red blood cell water fraction, and plasma water fraction. RESULTS: CVs for POC creatinine were 1.5- to 6-fold greater than those for plasma methods, in part due to meter-to-meter variation. Regression comparison of POC creatinine to IDMS results gave a standard error (S y|x) of 0.61 mg/dL (54 μmol/L), whereas regression of plasma enzymatic creatinine to IDMS was S y|x 0.16 mg/dL (14 mol/L). By univariate analysis, bilirubin, creatine, drugs, pO 2, pH, plasma water fraction, and hematocrit were not found to contribute to method differences. However, multivariate analysis revealed that IDMS creatinine, red blood cell and plasma water fractions, and hematocrit explained 91.8% of variance in POC creatinine results. CONCLUSIONS: These data suggest that whole-blood POC creatinine measurements should be used with caution. Negative interferences observed with these measurements could erroneously suggest adequate renal function near the decision threshold, particularly if estimated glomerular filtration rate is determined. Disparity between whole-blood and plasma matrices partially explains the discordance between whole-blood and plasma creatinine methods.
UR - http://www.scopus.com/inward/record.url?scp=80055076954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055076954&partnerID=8YFLogxK
U2 - 10.1373/clinchem.2011.165480
DO - 10.1373/clinchem.2011.165480
M3 - Article
C2 - 21920914
AN - SCOPUS:80055076954
SN - 0009-9147
VL - 57
SP - 1566
EP - 1573
JO - Clinical chemistry
JF - Clinical chemistry
IS - 11
ER -